Eckert & Ziegler stock wins GMP approval for Actinium-225

Published on 11/03/2026 at 10:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock gains a new production milestone after its subsidiary secures GMP authorization for Actinium-225. The approval supports clinical supply.

Ac-225 milestone expands supply options

Eckert & Ziegler Therapeutics received authorization to manufacture Actinium-225 under Good Manufacturing Practice standards.
The production chain combines radium irradiation in the Czech Republic with GMP processing in Braunschweig.
A Chinese joint venture plans commercial-scale Ac-225 production after initial operations begin in early 2027.

Eckert & Ziegler, DE0005659700, Illustration mit AI erstellt.

Eckert & Ziegler Therapeutics GmbH, a wholly owned subsidiary of Eckert & Ziegler SE, received manufacturing authorization for Actinium-225 on October 28, 2026. The certification confirms that the production process meets Good Manufacturing Practice standards and facilitates the use of the radioisotope in investigational patient treatments, according to the Deutsche Börse EQS News release.

From approval to production scale

Actinium-225 is an alpha emitter used in targeted radiopharmaceutical research. Eckert & Ziegler said the regulatory milestone moves its activity from initial production runs toward routine GMP manufacturing, giving clinical and commercial programs a supply platform to build on.

The production route starts with cyclotron irradiation of Radium-226 at the Nuclear Physics Institute of the Czech Academy of Sciences in ?ež. The irradiated material is then processed at the company's Braunschweig site. Isotope Technologies Dresden, the group's hot-cell division, supports both locations with specialized systems.

The company also highlighted measures aimed at making output more predictable. Its process limits long-lived impurities such as Actinium-227 and Thorium-229, while recovered Radium-226 can be returned to the production cycle. Eckert & Ziegler said this approach reduces reliance on constrained precursor inventories and can limit radioactive waste.

Expansion plans add an international dimension. A newly opened facility of the group's Qi Kang Medical Technology joint venture in Jintan, China, is intended to become the country's first commercial-scale Ac-225 production site. The second phase is planned after initial operations begin in early 2027. The company also said additional capacity could be considered at its radiopharmaceutical site near Boston and in Germany.

Management framed the authorization as a supply milestone rather than a completed commercial rollout. The regulatory step supports clinical availability and future capacity planning, but the announcement does not provide revenue or earnings targets for Ac-225. For investors, the potential opportunity remains linked to the progress of radiopharmaceutical programs and the pace at which new production capacity becomes operational.

The real-time quote of Eckert & Ziegler stock stood at 13.32 euros on Lang & Schwarz at 10:03 CET on Tuesday, November 3, 2026, 1.11 percent below the Xetra close of Monday, November 2.